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Abstract
Objective: Although electronic medical records (EMRs) have facilitated care for children with juvenile idiopathic
arthritis (JIA), analyses of treatment outcomes have required paper based or manually re-entered data. We have
started EMR discrete data entry for JIA patient visits, including joint examination and global assessment, by
physician and patient. In this preliminary study, we extracted data from the EMR to Xenobase™ (TransMed
Systems, Inc., Cupertino, CA), an application permitting cohort analyses of the relationship between global
assessment to joint examination and subtype.
Methods: During clinic visits, data were entered into discrete fields in ambulatory visit forms in the EMR
(EpicCare™, Epic Systems, Verona, WI). Data were extracted using Clarity Reports, then de-identified and uploaded
for analyses to Xenobase™. Parameters included joint examination, ILAR diagnostic classification, physician global
assessment, patient global assessment, and patient pain score. Data for a single visit for each of 160 patients over a
2 month period, beginning March, 2010, were analyzed.
Results: In systemic JIA patients, strong correlations for physician global assessment were found with pain score,
joint count and patient assessment. In contrast, physician assessment for patients with persistent oligoarticular and
rheumatoid factor negative patients showed strong correlation with joint counts, but only moderate correlation
with pain scores and patient global assessment. Conversely, for enthesitis patients, physician assessment correlated
strongly with pain scores, and moderately with joint count and patient global assessment. Rheumatoid factor
positive patients, the smallest group studied, showed moderate correlation for all three measures. Patient global
assessment for systemic patients showed strong correlations with pain scores and joint count, similar to data for
physician assessment. For polyarticular and enthesitis patients, correlation of patient global assessment with pain
scores was strong. Moderate correlations were found between patient global assessment and joint count in
oligoarticular and polyarticular patients.
Conclusion: Data extraction from the EMR is feasible and useful to evaluate JIA patients for indicators of treatment
responsiveness. In this pilot study, we found correlates for physician global assessment of arthritis differed,
according to disease subtype. Further data extraction and analyses will determine if these findings can be
confirmed, and will assess other outcome measures, compare longitudinal responses to treatment, and export
extracted data to multi-center databases.
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Juvenile idiopathic arthritis (JIA) is characterized by
joint inflammation with onset at or before sixteen years
of age [1]. Recent studies of biologic agents [2,3], have
relied upon a core set of outcome measures, including
components of physical examination, physician and
patient global assessment, and pain scores [4]. Other
disease status measures validated to measure remission
[5] and define minimally active disease [6] have found
that, despite current treatment, many children, including
those with initial response, have disease recurrences,
measured by remission criteria [7].
Physician global assessment is an important compo-
nent of all these outcome measures, distinct from joint
counts, patient pain assessment, and other components.
Physician and patient global assessments have been used
to define minimal disease activity [6]. Studies have not
determined the extent to which physician global assess-
ment correlates with joint counts or pain assessments,
depending upon JIA subtype. The advent of the electro-
nic medical record (EMR) permits data extraction to
address this type of question more efficiently than per-
mitted by a study of paper based records.
Since 2008, we have used an EMR to document all
outpatient visits, resulting in more rapid and better
organized access to medical information. We recently
incorporated the ability to enter discrete data for all vis-
its of children with juvenile idiopathic arthritis. In addi-
tion to extracting data in preparation for participation
in multi-center studies, we have started to analyze
extracted data concerning clinical status and assessment
of JIA patients. In this preliminary study, we used EMR
data extraction to study the relationship of physician
global assessment to patient global assessment and pain
scores in patients with different JIA subtypes.
Patients and methods
Patients
We studied data for all patients meeting ILAR diagnos-
tic criteria for juvenile idiopathic arthritis [8] seen by M.
M. and M.K.G. at Children’s Memorial Hospital pedia-
tric rheumatology clinics for 2 months starting March
2010. Patients in the Undifferentiated arthritis category
were not included because of heterogeneous characteris-
tics of these patients. In the other ILAR subtypes, 160
patients were seen.
Demographic and disease characteristics
Age data (birth date, date of each visit) were extracted.
Additional extractable disease characteristics consisted of
diagnostic subtype, joint count (active joints, as defined
in reference [4]), pain score, physician and patient global
assessment. ANA, rheumatoid factor (RF), and B27 status
had been tested within the first 4 months of diagnosis
and available (as noted in parentheses) for the subgroups
as follows: 18 systemic patients (18 ANA, 12 RF, 0 B27);
63 oligoarticular persistent patients (59 ANA, 43 RF, 21
B27); 6 oligoarticular extended patients (6 ANA, 5 RF, 2
B27); 40 RF negative polyarticular patients (38 ANA, 35
RF, 15 B27); 12 RF positive polyarticular patients (12
ANA, 12 RF, 6 B27); 3 psoriatic arthritis patients (3
ANA, 3 RF, 2 B27), 18 enthesitis patients (18 ANA, 15
RF, 15 B27). Per cent positive for each test is expressed
as per cent of all patients in the subgroup.
Physician and patient assessment
Physician global assessment of overall disease activity [4]
used a scale from 0 to 10. Patient pain was rated on a
Likert scale (with 0 = no pain and 10 = very severe
pain) in response to the question “By giving a number
between 0 and 10, with 0 being no pain and 10 being
the worst possible pain, how much pain on average have
you experienced from your arthritis over the past
week?” Patient global assessment was rated on a Likert
s c a l e( w i t h0=d o i n gv e r yp o o r l ya n d1 0=d o i n gv e r y
well) in response to the question “By giving a number
between 0 and 10, with 0 being doing very poorly and
10 being doing very well, how have you experienced
your arthritis in general over the past week? Include not
only pain, but also how you feel about your arthritis,
how having arthritis affects your getting along with
family and friends, and how well you can move around.”
Of the 160 patients, 132 (83%) self reported pain and
global assessments (13.0 ± 4.0 years). Of the other 28
patients (6.3 ± 2.7 years), mothers of 26 patients
reported, and fathers reported for 2 patients.
Data Entry into the Electronic Medical Record
Since July 2008, all patient visits have been documented
in an EMR (EpicCare™, Epic Systems, Verona, WI).
Starting in 2010, a discrete data structure (called flow
sheet rows in the Epic EMR) for JIA patients, named
RHE modules, for JIA patients has been incorporated
into the EMR, based upon the same data entry structure
in use at Cincinnati Children’s Hospital. All patients
with JIA have disease subtype (Figure 1), joint examina-
tion and related clinical data entered as discrete data
Figure 1 Appearance of the flow sheet rows for diagnosis
within the EpicCare™ EMR. Entry of ILAR diagnosis is more
accurate than can be accommodated by the ICD-9 system,
implemented primarily for billing purposes. The ICD-9 system, for
example, has no specific code for systemic JIA.
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each outpatient encounter. During the period of study,
3.75% of assessments were incomplete, reflecting adjust-
ment of physican work flows to the new data entry
method.
Data Extraction from the Electronic Medical Record
A System Development Lifecycle process was established
by the Department of Information Technology, Chil-
dren’s Memorial Research Center for data extraction
(Figure 2). Once flow sheet rows were established, an
Extract, Transform, Load (ETL) procedure employed
data queries that extracted relevant data, which was
then de-identified prior to uploading to Xenobase™.
Data is extracted each month for all RHE modules.
Xenobase
Data was analyzed using the XenoBase-BioIntegration
Suite (Xenobase™), an application residing in servers
maintained by the Xenobase team, CMRC. Xenobase,
developed in the Program of Translational Medicine at
the Van Andel Research Institute, and available com-
mercially (TransMed Systems, Inc., Cupertino, CA), pro-
vides a common interface for consolidating disparate
clinical, preclinical and molecular data; it provides statis-
tical and graphical data analytic functions (Figure 3). To
provide patient privacy, Xenobase uses an offset of up
to 45 days applied to all uploaded patient dates (includ-
ing birthdates). With IRB approval, this offset was re-
identified, permitting retrieval of legacy paper based
data (dates of onset of symptoms and diagnosis for
Figure 2 System Development Lifecycle. See Methods for explanation. Development initially affected appearance of the ambulatory EMR by
adding forms for entry of specific values for the joint examination, physician and patient global assessment, and patient pain score. The ETL
(extract, transform, load) process was implemented external to both the EMR source and analytic software target.
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data quality validation.
Statistical methods
Descriptive statistics are presented as median (mini-
mum, maximum) for continuous variables or frequency
(percentage) for categorical variables. We used Spear-
mann Rank correlation coefficients to measure pair-
wised correlations among physician assessment and
patient pain score, global assessments, and joint counts
for all subtypes except extended oligoarticular and psor-
iatic arthritis, due to the small numbers of patients in
those groups. Correlations were considered strong for
values >0.7, moderate for 0.4 - 0.7, and weak for <0.4.
All statistical analyses were performed using SAS
® ver-
sion 9.2 (SAS Institute, Inc., Cary, NC).
Results
Patients
We analyzed data extracted from 160 patients (Table 1).
Racial and ethnic group distributions (Table 1) were
notable for the paucity of African American and Asian
patients seen with arthritis, relative to their representa-
tion among outpatients seen in specialty clinics at Chil-
dren’s Memorial Hospital (data not shown). In addition,
Hispanic patients tended to have either oligoarticular or
polyarticular disease, more than other subtypes.
Half of children with enthesitis related arthritis were
ANA positive. Few patients with non-polyarticular dis-
ease were rheumatoid factor positive. One third of
enthesitis related arthritis patients were B27 positive.
Although no discernible differences among the subtypes
were found for median scores for physician global
assessment, patient global assessment, or patient pain
s c o r e( T a b l e2 ) ,r e l a t i o n s h i p s between physician assess-
ment and other parameters were found for particular
disease subtypes, as noted below.
Physician Global Assessment in JIA subtypes
Correlation of physician assessment with other outcome
measures varied with JIA subtype (Table 3). In systemic
JIA patients, strong correlations were found for pain
scores, joint count and patient assessment. In contrast,
physician assessment for patients with persistent oligoar-
ticular and rheumatoid factor negative patients showed
strong correlation with joint counts, but moderate cor-
relation with pain scores and patient global assessment.
Conversely, for enthesitis patients, physician global
assessment correlated strongly with pain scores, and
moderately with joint count (and, similarly to persistent
oligoarticular and rheumatoid factor negative polyarticu-
lar patients, moderately with patient global assessment).
Rheumatoid factor positive patients, the smallest group
studied, showed only moderate correlation for all three
measures.
Figure 3 Appearance of a data query window within the
Xenobase™ analytic software. Data queries, based upon JIA
subtype, can be carried out on uploaded data extracted from the
EMR.
Table 1 Demographic and disease characteristics
Systemic Oligo-p Oligo-e RF- poly RF+ poly Psoriatic Enthesitis
N 18 63 6 40 12 3 18
Age (yrs) 10.7 (5.8, 19.9) 9.9 (2.6, 18.6) 15.3 (10.8, 21.1) 11.2 (3.5,1 9.6) 13.5 (8.9,20.1) 12.9 (8.6,17.6) 17.0 (9.7, 21.2)
Gender (F/M) 8/10 52/11 5/1 34/6 12/0 2/1 9/9
Onset age (yrs) 5.5 (0.9, 13.0) 3.7 (0.8, 15.8) 8.2 (1.6, 14.8) 4.5 (1,15.6) 11.2 (6.7,15.6) 7.3 (6.3,13.0) 10.3 (3.0, 15.6)
Diagnostic age (yrs) 6.1 (1.0, 13.3) 4.3 (1, 16.6) 9.2 (1.9, 15.3) 5.4 (1.3, 17.3) 11.8 (6.9,16.1) 7.4 (7.3,13.4) 13.2 (9.7, 18.4)
Duration from diagnosis (yrs) 0.1 (0,1.1) 0.3 (0, 10.0) 0.3 (0, 2.0) 0.4 (0.0, 5.4) 0.4 (0,1.0) 0.3 (0.2,1.0) 2.1 (0, 5.3)
ANA+ n (%) 4 (22%) 36 (57%) 4 (67%) 15 (37.5%) 7 (58%) 1 (33%) 9 (50%)
RF+ n (%) 0 (0%) 1 (1.5%) 1 (16.7%) 0 (0%) 12 (100%) 1 (33%) 1 ((5.6%)
B27+ n (%) n/a 1 (1.5%) 1 (16.7%) 0 (0%) 0 (0%) 0 (0%) 6 (33%)
Race/Ethn.
White/non-Hispanic 14 48 6 32 8 2 14
Hispanic 17 73 2
African American 21 1 1
Asian 13 1
Other 41 1
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Correlation of patient assessment with pain scores and
joint counts also varied with JIA subtype (Table 4). For
systemic patients, patient assessment showed strong cor-
relations with pain scores and joint count, similar to
data for physician assessment. For polyarticular and
enthesitis patients, correlation of patient global assess-
ment with pain scores was strong. Moderate correlations
were found between patient global assessment and joint
count in oligoarticular and polyarticular patients.
Discussion
The aim of this study was to determine the extent to
which physician global assessment correlates with pain
and joint count for JIA patients with different subtypes,
using data extracted from the electronic medical record.
We found the extraction process efficient, permitting a
study too time consuming to perform in our center, if
data were only available from paper records. Distribu-
tion of JIA subtypes was similar to that previously
reported [9], except for fewer numbers of psoriatic
arthritis patients, perhaps because of different ethnic
distributions or shorter period of time for data collec-
tion in our study. Half of our enthesitis patients were
ANA positive, possibly a result of small sample size.
Validating data was necessary to ensure data extrac-
tion yielded identical target and source data. For exam-
ple, we found incorrect EMR formatting caused some
data appear to be absent, when physician or patient glo-
bal assessment was entered as zero. This was easily cor-
rected, but would have been missed had there not been
a validation process. When dates of disease onset and
diagnosis were prior to EMR implementation, requiring
data extraction from paper records, we used at least two
inspections of the data. Although prospective studies
eventually will not derive data from paper records, data
validation from EMR sources and targets will always be
necessary, if only because necessary EMR software
upgrades have potential to alter data flow from source
to target applications. Re-identification of de-identified
data is also critical for data validation in research using
data extracted from EMRs. To verify that data contents
and formats have been maintained from the moment of
data entry into the EMR to the time of data uploading
to the data target, cross checking against data from sev-
eral re-identified patients isb e s tc a r r i e do u tb yv i s u a l
comparisons by the investigator.
In the current study, we found physician global assess-
ment of persistent oligoarticular and rheumatoid factor
negative polyarticular patients strongly correlated with
joint count but moderately with patient pain scores and
global assessment (Table 3). However, patient assess-
ments showed higher correlation with pain scores than
joint counts in polyarticular patients (Table 4), raising
the possibility that these patients factored pain more
than extent of arthritis into their global assessments. In
contrast to these JIA subtypes, only for systemic JIA
patients were there strong correlations between physi-
cian global assessments and all the other outcome mea-
sures tested (Table 3). This possibly reflects differences
in disease characteristics in this subtype compared to
others, although low joint counts in this group probably
accounted for the high correlation coefficients between
physician and patient assessments.
In contrast to oligoarticular and rheumatoid factor
negative patients, in enthesitis patients we found a
strong correlation between physician global assessment
and pain score, rather than joint count. Most likely,
enthesitis contributed to these correlations. A quantita-
tive measure of enthesitis on physical examination, that
Table 2 Values of outcome measures
Systemic Oligo-p Oligo-e RF- poly RF+ poly Psoriatic Enthesitis
N 18 63 6 40 12 3 18
Physician global assessment 3 (0,10) 2 (0,10) 4.5 (1,7) 3 (0,9) 2 (0,8) 0 (0,1) 3 (0,7)
Patient global assessment 8 (0,10) 9 (3,10) 5 (3,9) 8 (3,10) 8 (1,10) 9 (4,10) 7.75 (0, 10)
Patient pain score 2.5 (0,8) 1 (0,8) 5 (2,7) 2 (0,8) 2 (0,9.5) 0 (0,2) 4 (0,10)
Joint Count 0.5 (0,19) 0 (0,4) 7.5 (0,15) 1 (0,20) 2.5 (0,10) 0 (0,0) 0 (0,2)
Joint Count = 0 n (%) 9 (50%) 35 (56%) 2 (33%) 18 (45%) 5 (42%) 3 (100%) 10 (56%)
Table 3 Spearman’s correlations between Physician Global Assessment and other outcome measures in JIA subtypes
Systemic Oligo-p RF- poly RF+ poly Enthesitis
Physician Global Assessment vs.
pain score 0.76 0.45 0.55 0.48 0.89
joint count 0.77 0.84 0.84 0.43 0.69
patient global assessment -0.89 -0.62 -0.66 -0.48 -0.56
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is lacking, perhaps because of difficulties inherent in
validation. Correlations between pain scores and joint
counts in all JIA subtypes tended to be lower than other
correlations (data not shown), possibly because pain
assessment during clinic visits can be insensitive, sug-
gested by a study using daily pain diaries [10].
Physician global assessment, while a subjective inter-
pretation of patient status, has been used as a compo-
nent of outcome scores, validated for drug studies [4]
and JIA remission criteria [11]. Few investigators have
explored its relationship to other outcome score compo-
nents. In one study with findings similar to ours, Bernt-
son et al found a strong relationship with joint count
[12] in 312 Scandinavian patients with all JIA subtypes,
excluding systemic onset. This study did not compare
physician global assessment to patient global assessment
or pain scores, as it addressed the role of joint size in
physician assessment.
We found no differences among JIA subtypes for data
distributions of physician or patient global assessments,
or for joint count, perhaps because of small sample sizes
and large numbers of patients with zero joint counts.
Findings from this preliminary study need to be con-
firmed with studies of larger numbers of patients, which
may identify differences among subgroups. We did not
characterize whether physician assessment correlated to
medication status; multi-center longitudinal studies may
be better able to address this question. Finally, although
it is possible that physician assessment varied, when we
analyzed data from patients by physician, no such varia-
bility was found.
Ours is one of the first studies of JIA patients to use
the EMR as a source of data, which can be used for
quality improvement studies [13], as has been used for
adults with arthritis [14]. While quality studies for chil-
dren with arthritis using EMR derived data remain to be
published [15], the Child Arthritis and Rheumatology
Research Alliance is establishing registries for childhood
rheumatic diseases, based upon widespread interest and
participation of pediatric rheumatologists [16,17].
In conclusion, we have established extractable clinical
data in electronic medical records for the purpose of
monitoring the status of JIA patients. In this preliminary
study, we found correlates of physician assessment vary
with disease subtype. We anticipate adding other
response measures and using extracted data to contri-
bute to multi-center national registries.
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